Physicians at the University of Rochester Medical Center (URMC) Strong Epilepsy Center were involved in the recent approval of a new treatment for epilepsy. The implantable medical device - called the Responsive Neurostimulator System (RNS) - monitors brain activity and can detect and counteract seizures.
URMC was one of only 28 sites in the country to conduct clinical trials of RNS, which was developed by the California-based company Neuropace. The research showed that the device decreases the number of monthly seizures by nearly 38 percent. URMC neurologists Michel Berg, M.D. and James Fessler, M.D., and neurosurgeon Web Pilcher, M.D., Ph.D. were involved in the study.
This is the first FDA-approved brain implant for epilepsy that responds to the brain's activity,
said Berg, an associate professor of Neurology. For patients who are unable to control their seizures with medications or are not eligible for resective surgery, this device could provide an important treatment option.